Consumer Feels Like...
Health Care: Drugs
Elan Corp PLC (ELN: NYSE)
$13.17 -0.27 | -2.01%
02/09/12 - 04:00 PM ET
4.23M / 2.88M
Vol / Avg. Vol:13.41 / 13.44
Open / Prev. Close:13.00 - 13.61
Today's Range:6.10 - 14.40
52 Wk Range:-2.18%
Performance YTD:TheStreet Rating:
Portfolios with ELN
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics
- ContributorRelative Strength Trades fo...
- ContributorStocks At New 52-Week Highs...
- ProRobert Bruce
- ContributorTechnical Setups for the We...
- Contributor10 Health Care Stocks With ...
- Userwhatnow
- Userfillip Portfolio 1
- ContributorCharts Of The Week 8-20-2010
- UserPART 5 JPMorgan 28th Annual...
Latest ELN Headlines from TheStreet
- Medivation Shrugs Off Alzheimer's Setback as Investors Eye New Prostate Cancer Data 01.17.12 | 09:01 am
- 7 Relative Strength Stocks for 2012 12.29.11 | 05:12 pm
- 7 Stocks Hitting New 52-Week Highs 12.21.11 | 01:12 pm
- Your Vote Counts: Who is the Worst Biotech CEO of 2011? 12.01.11 | 10:12 am
- Good Biotech Stocks for a Bear Market 08.09.11 | 08:08 am
- Lilly Study Imperils Alzheimer's Drugs 07.27.11 | 11:07 am
- Biogen Earnings: Tysabri Sales Impress 07.26.11 | 08:07 am
- Alkermes Offers Post-Merger Vision 07.18.11 | 02:07 pm
- 10 Stocks to Watch: Tyson, Dollar Thrifty 05.09.11 | 08:05 am
- Alkermes to Buy Elan Unit for $960M 05.09.11 | 07:05 am
Press Releases for ELN
- Elan Reports Fourth Quarter And Full-Year 2011 Financial Results - Business Wire 02.08.12 | 02:02 am
- Elan To Present At The Leerink Swann 2012 Global Healthcare Conference - Business Wire 02.01.12 | 04:02 pm
- ASCEND Study To Evaluate The Effectiveness Of TYSABRI® (natalizumab) As A Treatment For Secondary-Progressive Multiple Sclerosis - Business Wire 01.26.12 | 08:01 am
- FDA Updates TYSABRI® (natalizumab) Label To Include Anti-JC Virus Antibody Status As A PML Risk Factor - Business Wire 01.20.12 | 04:01 pm
- University College Dublin And Elan Announce Initiative To Create Leadership In Biotechnology - Business Wire 12.12.11 | 02:12 am
- Elan Provides An Update On ELND005 (Scyllo-inositol) - Business Wire 11.29.11 | 05:11 pm
- Cambridge-Elan Centre For Research Innovation And Drug Discovery Launched - Business Wire 11.28.11 | 02:11 am
- Elan Reports Third Quarter 2011 Financial Results - Business Wire 10.27.11 | 02:10 am
- Biogen Idec And Elan Receive Notification Of PDUFA Date Extension - Business Wire 10.20.11 | 08:10 am
- Data About Early Use And Long-Term Benefit Of TYSABRI Presented At 5th Joint Triennial Congress Of ECTRIMS And ACTRIMS - Business Wire 10.19.11 | 02:10 am
Partner Headlines for ELN
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and Eli Lilly & Company - Press Releases - Zacks 02.06.12 | 09:02 am
- The Zacks Analyst Blog Highlights: Pfizer, Biogen Idec, Elan, Novartis and Roche - Press Releases - Zacks 02.01.12 | 09:02 am
- Benzinga's M&A Chatter for Monday December 19, 2011 - Benzinga 12.19.11 | 04:12 pm
- Questor Pharmaceuticals: Even In A Bad Market, Fantastic Growth Looks Attractive - Seeking Alpha 11.25.11 | 08:11 am
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan Corporation, Sprint, AT&T and Verizon - Press Releases - Zacks 11.16.11 | 09:11 am
- 10 Overvalued Healthcare Stocks - Seeking Alpha 10.25.11 | 08:10 am
- FDA Extends Date for Biogen Drug - Analyst Blog - Zacks 10.21.11 | 06:10 pm
- Alkermes Buys Elan's EDT Unit - Analyst Blog - Zacks 09.19.11 | 06:09 pm
- UPDATE 1-Elan adds new directors after years of pressure - Reuters 09.15.11 | 12:09 pm
- PDL BioPharma Guides Q3 Sales - Analyst Blog - Zacks 09.12.11 | 10:09 am
